Dianthus Tx appoints Susan Kalled as CSO

17 January 2023

Dianthus Therapeutics, a biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, today announced the appointment of Susan Kalled, as chief scientific officer.

Based in Waltham, Massachusetts, and New York City, Dianthus came out of stealth in May 2022, having been since founding in 2019, as it announced the completion of its $100 million Series A financing.

"We are thrilled to have Susan join the team at such a pivotal time for the company," said Marino Garcia, president and chief executive of Dianthus Therapeutics, adding: "Her expertise in shaping complement and immunology pipelines across small and large biotech companies will be invaluable as we advance our lead program through Phase I clinical studies this year and as we further develop our pipeline with novel targets and next-generation complement inhibitors."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK